Danielle Brill
Stock Analyst at Truist Securities
(1.99)
# 3,077
Out of 4,910 analysts
84
Total ratings
39.73%
Success rate
-7.91%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRON Disc Medicine | Initiates: Buy | $86 | $60.97 | +41.06% | 6 | Jul 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Buy | $385 | $326.13 | +18.05% | 1 | Jul 21, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $37.22 | +28.96% | 8 | Jul 21, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $56 | $38.43 | +45.72% | 1 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Buy | $64 | $22.99 | +178.38% | 2 | Jul 21, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $163 | $133.66 | +21.95% | 6 | Jul 21, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $66 | $46.19 | +42.89% | 1 | Jul 21, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | $30 | $15.63 | +91.94% | 1 | Jul 21, 2025 | |
| JCAP Jefferson Capital | Initiates: Buy | $24 | $16.94 | +41.68% | 1 | Jul 21, 2025 | |
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $15.38 | +238.10% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $14.47 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $59.67 | +32.39% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $9.09 | +98.02% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $36 | $18.39 | +95.76% | 4 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $13.32 | +1,026.13% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $130.98 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $8.77 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $476.95 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $575.42 | +5.14% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $23.27 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $31.19 | +60.31% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $40.55 | +25.79% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $5.78 | +1,630.10% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $47.08 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.62 | - | 5 | Jun 27, 2023 |
Disc Medicine
Jul 21, 2025
Initiates: Buy
Price Target: $86
Current: $60.97
Upside: +41.06%
Alnylam Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $385
Current: $326.13
Upside: +18.05%
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $37.22
Upside: +28.96%
Palvella Therapeutics
Jul 21, 2025
Initiates: Buy
Price Target: $56
Current: $38.43
Upside: +45.72%
Tectonic Therapeutic
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $22.99
Upside: +178.38%
Neurocrine Biosciences
Jul 21, 2025
Initiates: Buy
Price Target: $163
Current: $133.66
Upside: +21.95%
BridgeBio Pharma
Jul 21, 2025
Initiates: Buy
Price Target: $66
Current: $46.19
Upside: +42.89%
Centessa Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $15.63
Upside: +91.94%
Jefferson Capital
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $16.94
Upside: +41.68%
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $15.38
Upside: +238.10%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.47
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $59.67
Upside: +32.39%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $9.09
Upside: +98.02%
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $18.39
Upside: +95.76%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $13.32
Upside: +1,026.13%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $130.98
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $8.77
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $476.95
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $575.42
Upside: +5.14%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $23.27
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $31.19
Upside: +60.31%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $40.55
Upside: +25.79%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $5.78
Upside: +1,630.10%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $47.08
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.62
Upside: -